Type 1 Diabetes Drug Market Research Report by Form (Insulin Therapy and Oral Medication), by End User (Drugstore and Hospital) - Global Forecast to 2025 - Cumulative Impact of COVID-19
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Type 1 Diabetes Drug Market is expected to grow from USD 13,668.00 Million in 2020 to USD 20,109.81 Million by the end of 2025.
2. The Global Type 1 Diabetes Drug Market is expected to grow from EUR 11,984.36 Million in 2020 to EUR 17,632.66 Million by the end of 2025.
3. The Global Type 1 Diabetes Drug Market is expected to grow from GBP 10,654.12 Million in 2020 to GBP 15,675.47 Million by the end of 2025.
4. The Global Type 1 Diabetes Drug Market is expected to grow from JPY 1,458,722.13 Million in 2020 to JPY 2,146,226.43 Million by the end of 2025.
5. The Global Type 1 Diabetes Drug Market is expected to grow from AUD 19,847.75 Million in 2020 to AUD 29,202.12 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Type 1 Diabetes Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Form, the Type 1 Diabetes Drug Market studied across Insulin Therapy and Oral Medication. The Insulin Therapy further studied across Long-Acting Insulin, Premix Analogs, and Rapid Acting Insulin. The Oral Medication further studied across Biguanides and Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.
Based on End User, the Type 1 Diabetes Drug Market studied across Drugstore and Hospital.
Based on Geography, the Type 1 Diabetes Drug Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Type 1 Diabetes Drug Market including Astellas Pharma Inc., Astrazeneca Plc, B.braun Melsungen Ag, Biocon Limited, Biodel, Inc., Diavacs, Inc., Janssen Pharmaceutica, Macrogenics, Inc., Merck & Co., Inc., Mylan N.V., Novo Nordisk A/s, Samsung Bioepis Co., Ltd., and Sanofi S.A..
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Type 1 Diabetes Drug Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Type 1 Diabetes Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Type 1 Diabetes Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Type 1 Diabetes Drug Market?
4. What is the competitive strategic window for opportunities in the Global Type 1 Diabetes Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Type 1 Diabetes Drug Market?
6. What are the modes and strategic moves considered suitable for entering the Global Type 1 Diabetes Drug Market?
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Type 1 Diabetes Drug Market is expected to grow from USD 13,668.00 Million in 2020 to USD 20,109.81 Million by the end of 2025.
2. The Global Type 1 Diabetes Drug Market is expected to grow from EUR 11,984.36 Million in 2020 to EUR 17,632.66 Million by the end of 2025.
3. The Global Type 1 Diabetes Drug Market is expected to grow from GBP 10,654.12 Million in 2020 to GBP 15,675.47 Million by the end of 2025.
4. The Global Type 1 Diabetes Drug Market is expected to grow from JPY 1,458,722.13 Million in 2020 to JPY 2,146,226.43 Million by the end of 2025.
5. The Global Type 1 Diabetes Drug Market is expected to grow from AUD 19,847.75 Million in 2020 to AUD 29,202.12 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Type 1 Diabetes Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Form, the Type 1 Diabetes Drug Market studied across Insulin Therapy and Oral Medication. The Insulin Therapy further studied across Long-Acting Insulin, Premix Analogs, and Rapid Acting Insulin. The Oral Medication further studied across Biguanides and Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.
Based on End User, the Type 1 Diabetes Drug Market studied across Drugstore and Hospital.
Based on Geography, the Type 1 Diabetes Drug Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Type 1 Diabetes Drug Market including Astellas Pharma Inc., Astrazeneca Plc, B.braun Melsungen Ag, Biocon Limited, Biodel, Inc., Diavacs, Inc., Janssen Pharmaceutica, Macrogenics, Inc., Merck & Co., Inc., Mylan N.V., Novo Nordisk A/s, Samsung Bioepis Co., Ltd., and Sanofi S.A..
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Type 1 Diabetes Drug Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Type 1 Diabetes Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Type 1 Diabetes Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Type 1 Diabetes Drug Market?
4. What is the competitive strategic window for opportunities in the Global Type 1 Diabetes Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Type 1 Diabetes Drug Market?
6. What are the modes and strategic moves considered suitable for entering the Global Type 1 Diabetes Drug Market?
1. PREFACE
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Form Outlook
3.4. End User Outlook
3.5. Geography Outlook
3.6. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL TYPE 1 DIABETES DRUG MARKET, BY FORM
6.1. Introduction
6.2. Insulin Therapy
6.2.1. Long-Acting Insulin
6.2.2. Premix Analogs
6.2.3. Rapid Acting Insulin
6.3. Oral Medication
6.3.1. Biguanides
6.3.1.1. Metformine
6.3.1.2. Metformine Extended-Release
6.3.2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
6.3.2.1. Canaglifozine
6.3.2.2. Dapagliflozine
6.3.2.3. Empagliflozine
6.3.2.4. Ertugliflozine
7. GLOBAL TYPE 1 DIABETES DRUG MARKET, BY END USER
7.1. Introduction
7.2. Drugstore
7.3. Hospital
8. AMERICAS TYPE 1 DIABETES DRUG MARKET
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. South Korea
9.10. Thailand
10. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. COMPETITIVE LANDSCAPE
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis
11.4. Competitor SWOT Analysis
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion
12. COMPANY USABILITY PROFILES
12.1. Astellas Pharma Inc.
12.2. Astrazeneca Plc
12.3. B.braun Melsungen Ag
12.4. Biocon Limited
12.5. Biodel, Inc.
12.6. Diavacs, Inc.
12.7. Janssen Pharmaceutica
12.8. Macrogenics, Inc.
12.9. Merck & Co., Inc.
12.10. Mylan N.V.
12.11. Novo Nordisk A/s
12.12. Samsung Bioepis Co., Ltd.
12.13. Sanofi S.A.
13. APPENDIX
13.1. Discussion Guide
13.2. License & Pricing
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Form Outlook
3.4. End User Outlook
3.5. Geography Outlook
3.6. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL TYPE 1 DIABETES DRUG MARKET, BY FORM
6.1. Introduction
6.2. Insulin Therapy
6.2.1. Long-Acting Insulin
6.2.2. Premix Analogs
6.2.3. Rapid Acting Insulin
6.3. Oral Medication
6.3.1. Biguanides
6.3.1.1. Metformine
6.3.1.2. Metformine Extended-Release
6.3.2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
6.3.2.1. Canaglifozine
6.3.2.2. Dapagliflozine
6.3.2.3. Empagliflozine
6.3.2.4. Ertugliflozine
7. GLOBAL TYPE 1 DIABETES DRUG MARKET, BY END USER
7.1. Introduction
7.2. Drugstore
7.3. Hospital
8. AMERICAS TYPE 1 DIABETES DRUG MARKET
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. South Korea
9.10. Thailand
10. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. COMPETITIVE LANDSCAPE
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis
11.4. Competitor SWOT Analysis
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion
12. COMPANY USABILITY PROFILES
12.1. Astellas Pharma Inc.
12.2. Astrazeneca Plc
12.3. B.braun Melsungen Ag
12.4. Biocon Limited
12.5. Biodel, Inc.
12.6. Diavacs, Inc.
12.7. Janssen Pharmaceutica
12.8. Macrogenics, Inc.
12.9. Merck & Co., Inc.
12.10. Mylan N.V.
12.11. Novo Nordisk A/s
12.12. Samsung Bioepis Co., Ltd.
12.13. Sanofi S.A.
13. APPENDIX
13.1. Discussion Guide
13.2. License & Pricing
LIST OF TABLES
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 73. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 74. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 75. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 76. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 77. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 78. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 79. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 80. GLOBAL TYPE 1 DIABETES DRUG MARKET: SCORES
TABLE 81. GLOBAL TYPE 1 DIABETES DRUG MARKET: BUSINESS STRATEGY
TABLE 82. GLOBAL TYPE 1 DIABETES DRUG MARKET: PRODUCT SATISFACTION
TABLE 83. GLOBAL TYPE 1 DIABETES DRUG MARKET: RANKING
TABLE 84. GLOBAL TYPE 1 DIABETES DRUG MARKET: MERGER & ACQUISITION
TABLE 85. GLOBAL TYPE 1 DIABETES DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 86. GLOBAL TYPE 1 DIABETES DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 87. GLOBAL TYPE 1 DIABETES DRUG MARKET: INVESTMENT & FUNDING
TABLE 88. GLOBAL TYPE 1 DIABETES DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 89. GLOBAL TYPE 1 DIABETES DRUG MARKET: LICENSE & PRICING
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 73. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 74. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 75. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 76. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 77. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 78. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 79. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 80. GLOBAL TYPE 1 DIABETES DRUG MARKET: SCORES
TABLE 81. GLOBAL TYPE 1 DIABETES DRUG MARKET: BUSINESS STRATEGY
TABLE 82. GLOBAL TYPE 1 DIABETES DRUG MARKET: PRODUCT SATISFACTION
TABLE 83. GLOBAL TYPE 1 DIABETES DRUG MARKET: RANKING
TABLE 84. GLOBAL TYPE 1 DIABETES DRUG MARKET: MERGER & ACQUISITION
TABLE 85. GLOBAL TYPE 1 DIABETES DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 86. GLOBAL TYPE 1 DIABETES DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 87. GLOBAL TYPE 1 DIABETES DRUG MARKET: INVESTMENT & FUNDING
TABLE 88. GLOBAL TYPE 1 DIABETES DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 89. GLOBAL TYPE 1 DIABETES DRUG MARKET: LICENSE & PRICING
LIST OF FIGURES
FIGURE 1. GLOBAL TYPE 1 DIABETES DRUG MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL TYPE 1 DIABETES DRUG MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2020 (USD MILLION)
FIGURE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2020 (USD MILLION)
FIGURE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET: MARKET DYNAMICS
FIGURE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2020 VS 2025 (%)
FIGURE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2020 VS 2025 (USD MILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2025
FIGURE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2020 VS 2025 (USD MILLION)
FIGURE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, 2020 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, 2020 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2020 VS 2025 (USD MILLION)
FIGURE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2020 VS 2025 (USD MILLION)
FIGURE 22. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, 2020 VS 2025 (USD MILLION)
FIGURE 23. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, 2020 VS 2025 (USD MILLION)
FIGURE 24. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2020 VS 2025 (USD MILLION)
FIGURE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, 2020 VS 2025 (USD MILLION)
FIGURE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, 2020 VS 2025 (USD MILLION)
FIGURE 27. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, 2020 VS 2025 (USD MILLION)
FIGURE 28. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, 2020 VS 2025 (USD MILLION)
FIGURE 29. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2020 VS 2025 (%)
FIGURE 30. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2020 VS 2025 (USD MILLION)
FIGURE 31. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025
FIGURE 32. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, 2020 VS 2025 (USD MILLION)
FIGURE 33. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, 2020 VS 2025 (USD MILLION)
FIGURE 34. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 35. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 37. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 38. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 39. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 40. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 41. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 42. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 43. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 44. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 45. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 46. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 47. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 48. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 49. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 50. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 51. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 52. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 53. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 54. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 55. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 56. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 57. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 58. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 59. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 60. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 61. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 62. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 63. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 64. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 65. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 66. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 67. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 68. GLOBAL TYPE 1 DIABETES DRUG MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 69. GLOBAL TYPE 1 DIABETES DRUG MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 70. GLOBAL TYPE 1 DIABETES DRUG MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 71. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL TYPE 1 DIABETES DRUG MARKET, BY TYPE
FIGURE 1. GLOBAL TYPE 1 DIABETES DRUG MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL TYPE 1 DIABETES DRUG MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2020 (USD MILLION)
FIGURE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2020 (USD MILLION)
FIGURE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET: MARKET DYNAMICS
FIGURE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2020 VS 2025 (%)
FIGURE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2020 VS 2025 (USD MILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2025
FIGURE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2020 VS 2025 (USD MILLION)
FIGURE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, 2020 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, 2020 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2020 VS 2025 (USD MILLION)
FIGURE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2020 VS 2025 (USD MILLION)
FIGURE 22. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, 2020 VS 2025 (USD MILLION)
FIGURE 23. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, 2020 VS 2025 (USD MILLION)
FIGURE 24. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2020 VS 2025 (USD MILLION)
FIGURE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, 2020 VS 2025 (USD MILLION)
FIGURE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, 2020 VS 2025 (USD MILLION)
FIGURE 27. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, 2020 VS 2025 (USD MILLION)
FIGURE 28. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, 2020 VS 2025 (USD MILLION)
FIGURE 29. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2020 VS 2025 (%)
FIGURE 30. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2020 VS 2025 (USD MILLION)
FIGURE 31. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025
FIGURE 32. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, 2020 VS 2025 (USD MILLION)
FIGURE 33. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, 2020 VS 2025 (USD MILLION)
FIGURE 34. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 35. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 37. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 38. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 39. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 40. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 41. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 42. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 43. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 44. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 45. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 46. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 47. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 48. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 49. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 50. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 51. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 52. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 53. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 54. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 55. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 56. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 57. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 58. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 59. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 60. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 61. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 62. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 63. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 64. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 65. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 66. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 67. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 68. GLOBAL TYPE 1 DIABETES DRUG MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 69. GLOBAL TYPE 1 DIABETES DRUG MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 70. GLOBAL TYPE 1 DIABETES DRUG MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 71. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL TYPE 1 DIABETES DRUG MARKET, BY TYPE
